课题基金 / 基金详情

项目摘要

项目成果

LINDA M ZANGWILL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary The “Ocular Hypertension Treatment Study (OHTS 3): 20-year follow-up (Phase 3)” was designed to determine the incidence and severity of primary open angle glaucoma (POAG) in the longstanding OHTS cohort. and determine the frequency and severity of functional limitations associated with POAG. Moreover, this well-characterized cohort has precise information on the dates/timing of the development of POAG assessed by 3 glaucoma specialist endpoint committee members, as well as extensive data on self-reported functional limitations of its participants. Spectral domain optical coherence tomography (OCT), now the standard of care for detecting glaucomatous structural damage and change was included for the first time in OHTS as part of the OHTS 3 core visit. The objective of this secondary data analysis proposal is to analyze the OHTS 3 OCT scans and leverage the 20 years of OHTS data to provide guidance on how best to utilize OCT in the clinical management of glaucoma. Specific Aim 1 will determine whether review of macula scans improves POAG detection compared to the clinical standard review of VF and RNFL scans. With the increased focus on patient-reported outcomes as a key measure of treatment success, in Specific Aim 2 we will utilize the extensive quality of life (QOL) surveys from OHTS 3 and include OCT structural damage in models to predict functional limitations due to POAG. Finally, with a participant median age of 73 years at the OHTS 3 core visit, Specific Aim 3 will characterize structural damage and its determinants 10 and 15 years after the precise onset of POAG and compare it to age-related structural changes in these older subjects who did not develop POAG.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NEI Center Core Grant for Vision Research
Computational Ophthalmology and Biomedical Informatics
Administrative Core
OCT in the Ocular Hypertension Treatment Study: 20 Year Follow-up
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: